anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Human papillomavirus (HPV) has been established as a causative agent in the development of oral squamous cell carcinoma (OSCC). Specifically, HPV types 16 and 18 are known to be prevalent in oral cancers. This cross-sectional study aimed to determine the prevalence of HPV types 16 and 18 in OSCC cases in Qazvin province, Iran. Thirty-eight paraffin-embedded samples of OSCC were selected, and DNA extraction was performed using the Roche High Pure FFPE DNA isolation kit. The quality of the extracted DNA was assessed through PCR amplification of the human β-Globin gene. The HPV detection was carried out using SYBR green-based real-time PCR with GP5+ and GP6+ primers targeting the L1 region of HPV. The HPV genotyping was conducted on positive samples using specific primers. Statistical analysis was performed between HPV infection in OSCC and age, sex, and anatomical location. This study analyzed 38 biopsy specimens obtained from male and female OSCC patients, with an average age of 64 years. Among these samples, 13 tested positive for HPV, resulting in a prevalence rate of 34.2%. The age group with the highest HPV infection rate was 61-70 (10.5%) years. Notably, HPV type 16 was detected in 21.0% of samples, HPV type 18 in 10.5%, and other viral subtypes in 2.6%. No statistically significant correlation was found between HPV prevalence and gender or age. The findings indicated that 34.2% of OSCC samples in the Qazvin province harbor HPV, with types 16 and 18 being the most common in tumors affecting the tongue. Additionally, no association was observed between HPV infection and age or gender. To address HPV as a risk factor for OSCC, public health initiatives such as vaccination, awareness campaigns, and accessible healthcare services should be implemented. They are, furthermore, incorporating HPV DNA testing into practice.
Coronary artery disease (CAD) is one of the most common types of cardiovascular disease and can lead to a heart attack as plaque gradually builds up inside the coronary arteries, blocking blood flow. Previous studies have shown that polymorphisms in the PAI-1 gene are associated with CAD; however, studies of the PAI-1 3'-untranslated region, containing a miRNA binding site, and the miRNAs that interact with it, are insufficient. To investigate the association between miRNA polymorphisms and CAD in the Korean population based on post-transcriptional regulation, we genotyped five polymorphisms in four miRNAs targeting the 3'-untranslated region of PAI-1 using real-time PCR and TaqMan assays. We found that the mutant genotype of miR-30c rs928508 A > G was strongly associated with increased CAD susceptibility. In a genotype combination analysis, the combination of the homozygous mutant genotype (GG) of miR-30c rs928508 with the wild-type genotype (GG) of miR-143 rs41291957 resulted in increased risk for CAD. Also, in an allele combination analysis, the combination of the mutant allele (G) of miR-30c rs928508 and the wild-type allele (G) of miR-143 rs41291957 resulted in increased risk for CAD. Furthermore, metabolic syndrome and diabetes mellitus showed synergistic effects on CAD risk when combined with miR-30c rs928508. These results can be applied to identify CAD prognostic biomarkers among miRNA polymorphisms and various clinical factors.
The World Health Organization (WHO) in 2022 developed a fungal priority pathogen list. Candida auris was ultimately ranked as a critical priority pathogen. PubMed and Web of Science were used to find studies published from 1 January 2011 to 18 February 2021, reporting on predefined criteria including: mortality, morbidity (i.e., hospitalization and disability), drug resistance, preventability, yearly incidence, and distribution/emergence. Thirty-seven studies were included in the final analysis. The overall and 30-day mortality rates associated with C. auris candidaemia ranged from 29% to 62% and 23% to 67%, respectively. The median length of hospital stay was 46-68 days, ranging up to 140 days. Late-onset complications of C. auris candidaemia included metastatic septic complications. Resistance rates to fluconazole were as high as 87%-100%. Susceptibility to isavuconazole, itraconazole, and posaconazole varied with MIC90 values of 0.06-1.0 mg/l. Resistance rates to voriconazole ranged widely from 28% to 98%. Resistance rates ranged between 8% and 35% for amphotericin B and 0%-8% for echinocandins. Over the last ten years, outbreaks due to C. auris have been reported in in all WHO regions. Given the outbreak potential of C. auris, the emergence and spread of MDR strains, and the challenges associated with its identification, and eradication of its environmental sources in healthcare settings, prevention and control measures based on the identified risk factors should be evaluated for their effectiveness and feasibility. Global surveillance studies could better inform the incidence rates and distribution patterns to evaluate the global burden of C. auris infections.
The present invention relates to a veterinary medicine composition for preventing and curing coccidiosis. The final product is in a henna liquid form, which contains I<->0.01 to 1.0%(mol/ml) of iodine ions, 0.5 to 50%(V/V) of lactic acid, 0.1 to 40%(V/V) of tannic acid, and water as the rest. The preparation method for the composition comprises the steps: preparing iodine ion I<-> ionization induction liquid, preparing iodine ion I<-> solution, treating by lactic acid, treating by tannic acid and adding water to a constant volume. The composition kills cells in coccidian and can effectively and thoroughly kill coccidium forms at every development stages of the coccidium life history. Since the integrated synergistic action of the contained iodine ions I<->, lactic acid and tannic acid, the present invention can repair damaged mucosae of intestinal tracts, enhance livestock organism resistance, and restore the livestock growth ability without harm to livestock organisms. In conclusion, the composition is a green environmental protection medicine and is brought in line with WTO, with no prohibited drugs or components, no toxic and side effects, no residual drug, no drug holiday, no drug resistance, no cross drug resistance, quick and thorough therapeutic effects and no recurrence.
The invention relates to a transcutaneous or transgingival implant having a body 1 made of a bioinert material, whose subcutaneous or subgingival part 2 is anchored in bone tissue, and, in the region of the passage of the body 1 through the skin or mucosa 4, a ring 5 having at least a surface layer, which is contacted by the skin or mucosa, of a bioactive material. Bioinert materials such as titanium or dense, high-purity Al2O3-ceramic material permit good integration of the implant body with bone. The mechanical properties of these bioinert materials also permit their use for load-transmitting functions. Bioactive materials, such as hydroxyapatite ceramics or tricalcium phosphate ceramics, permit a more favourable deposition of tissue at the passage through the skin but their mechanical strength is too low. By providing the ring 5 of bioactive material on a semi-implant of bioinert material in the region of the passage of the implant through the skin or mucosa it is possible to utilise the more favourable tissue compatibility even for load-transmitting transcutaneous or transgingival implants. <IMAGE>
The invention relates to medicine, namely to the dentistry, in particular to a method for treating or preventing the diseases of periodontium in the children inhabiting the territories contaminated with xenobiotics. The method comprises the use of the oral baths with 15 % aqueous solution of antiseptic 3-4 times a day for 10 days. One hour following each oral bath, the combined drug containing lysozyme and dequalinium chloride, is taken in a form of the oral dispersible table. Since the first day of the treatment, hydrogel of methylsilicic acid is taken as a sorbent in 1.5-2 hours prior to the meals (used topically in oral cavity). Then the maintenance therapy is provided for 30 days (multivitamine complex and combined drug containing of calcium and vitamin D). If required, the maintenance therapy is repeated twice a year in the autumn and the spring.
Inaccuracy of medication histories and lack of knowledge on actual medication use results in confusion about medication regimens and medication mismanagement before- during - and after hospital admission. This phenomenon accounts for many readmissions, longer duration of admission and preventable and serious Adverse Drug Events (ADEs) as a result of Drug Related Problems (DRPs). Several studies show that discharge medication reconciliation (MR) and counseling by a pharmacy employee reduces the amount of discrepancies in the discharge prescription lists. Still, no unequivocal effect of MR on the occurrence of DRPs after discharge has been shown. This is due to a shift in underlying potential harmful discrepancies from mainly patient based (unintended nonadherence) to mainly system based (eg dispensing errors) and might be explained by (1) suboptimal transfer of information (2) an overload of information during a stressful situation and (3) difficulty to implement changes in medication at home. Therefore the reduction of DRPs, improvement of patients' medication knowledge and initial adherence can probably most effectively be addressed in a multifaceted integrated transmural intervention. Repetition of important information is the key to success. Moreover, the first weeks following hospital discharge are most crucial in preventing drug-related problems as patients could slip back in old medication schemes, or new problems may arise, such as emerging ADEs due to medication changes made during hospitalization.
Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Esomeprazole magnesium dihydrate 40 mg tablets test product, treatment 2= Esomeprazole magnesium dihydrate 40 mg tablets reference product.
A calcium phosphate self-setting cement is invented by using diffusion controlled solid liquid heterogeneous reaction between tetracalcium phosphate (Ca 4 (PO 4 ) 2 O, TTCP) fine powder and solution of di-potassium hydrogen phosphate (K 2 HPO 4 ). Fine powders of tetracalcium phosphate is introduced into the di-potassium hydrogen phosphate solution and homogenized well to form a cement paste. The cement paste was allowed to set at room temperature (25±5° C.). In the cement paste calcium is leached from the tetracalcium phosphate (TTCP) fine particles as Ca(OH) 2  into the aqueous phase. Leaching of calcium continues until the Ca/P ratio changes from 2 to 1.67, which corresponds to hydroxyapatite. Calcium hydroxide thus formed reacts with the phosphate ions (p0 4   3− ) that exist in the liquid phase, and the reaction leads to in-situ precipitation of hydroxyapatite as the reaction product, which leads to interparticle entanglement in the cement paste, thereby forming self-setting bone cement.
Recent evidence has shown that proteins in normal human urine can inhibit calcium oxalate (CaOx) kidney stone formation. Herein, we performed fast protein liquid chromatography (FPLC) to fractionate normal human urinary proteins using anion-exchange (DEAE) and size-exclusion (Superdex 200) materials. FPLC fractions (F1-F15) were examined by CaOx crystallization, growth, aggregation and crystal-cell adhesion assays. The fractions with potent inhibitory activities against CaOx crystals were then subjected to mass spectrometric protein identification. The data revealed that 13 of 15 fractions showed inhibitory activities in at least one crystal assay. Integrating CaOx inhibitory scores demonstrated that F6, F7 and F8 had the most potent inhibitory activities. NanoLC-ESI-Qq-TOF MS/MS identified 105, 93 and 53 proteins in F6, F7 and F8, respectively. Among them, 60 were found in at least two fractions and/or listed among known inhibitors with solid experimental evidence in the StoneMod database (https://www.stonemod.org). Interestingly, 10 of these 60 potential inhibitors have been reported with lower urinary levels in CaOx stone formers compared with healthy (non-stone) individuals, strengthening their roles as potent CaOx stone inhibitors. Our study provides the largest dataset of potential CaOx stone inhibitory proteins that will be useful for further elucidations of stone-forming mechanisms and ultimately for therapeutic/preventive applications.
Hyperuricemia (HUA) is one of the most common chronic diseases today, with a prevalence exceeding 14 % in both the United States and China. Current clinical treatments for HUA focus on promoting uric acid (UA) excretion and inhibiting UA production, but often neglect the strain on the liver and kidneys. The fruit of Alpinia oxyphylla (A. oxyphylla) is known to improve renal function, regulate metabolism, and exhibit anti-inflammatory effects; however, its effectiveness and mechanisms in treating HUA are not well understood. In this study, HUA mice induced by potassium oxonate and adenine were treated with A. oxyphylla polysaccharide (AFP) for 21 days. The levels associated with HUA were quantified using assay kits to evaluate the impact of AFP on HUA. Serum metabolomics and 16S rRNA sequencing were used to investigate the mechanisms by which AFP ameliorates HUA. The results showed that AFP treatment reduced abnormal biochemical levels, including UA, blood urea nitrogen, and creatinine, in HUA mice. AFP inhibited UA synthesis by regulating pyrimidine metabolism and the metabolism of alanine, aspartate and glutamate, reduced kidney inflammation, and promoted UA excretion by regulating intestinal flora. Thus, AFP appears to be an effective agent for alleviating HUA symptoms.
The present invention relates to a composition for anti-inflammation, skin itching relief, skin moisturizing, and antibacterial action, comprising a mixed culture strain of Lactobacillus sp. SDCM 1003 and Lactobacillus sp. SDCM 1105, a culture medium thereof, or an extract thereof as an active ingredient. A mixed culture strain of Lactobacillus sp. SDCM 1003 (Accession No. KCTC 14014BP) and Lactobacillus sp. SDCM 1105 (Accession No. KCTC 14200BP), a culture fluid or an extract thereof according to the present invention has no cytotoxicity, is effective in the treatment and prevention of inflammatory diseases by directly inhibiting the production of nitric oxide, and has a superior TSLP production inhibitory effect compared to tacrolimus, an immunosuppressive compound used for conventional atopic dermatitis, can be very effectively used for skin moisturizing purposes by effectively increasing the production of hyaluronic acid in skin cells, and has an excellent effect of effectively inhibiting the growth of pathogenic microorganisms and acne-causing bacteria, and thus can be advantageously used in cosmetics, food and pharmaceutical fields.
This longitudinal survey aims to demonstrate improvement in oral hygiene among a group of youth with visual impairment (VI) achieved by repeated oral hygiene training, compare their progress with healthy peers (CG) and assess their oral health knowledge. In 100 VI (55♀, 45♂; ± 17.8 years) and 45 CG (23♀, 22♂; ± 17.2 years) oral hygiene training and a Quigley-Hein Plaque Index (QHI) rating were repeated six times at three-month intervals. The VI were divided into four subgroups according to the toothbrush hardness/type. A questionnaire was given to both groups. Appropriate statistical analyses were performed at 5% significance level. Both groups showed reduction in QHI, the VI had overall higher QHI values than CG. Use of an electric toothbrush in VI led to lower QHI in the last examination (p < 0.03). 69% of participants recommended dental specialists to improve communications by acquiring more illustrative aids. VI changed toothbrush less often (p < 0.02). A higher incidence of dental plaque was confirmed in VI compared to CG. After education and individual training, gradual plaque reduction has occurred in both groups. Using an electric toothbrush in VI resulted in better QHI outcomes. Repetitive preventive intervention in youth with VI helped them to adopt healthier oral hygiene habits.
FIELD: medicine, combustiology, anesthesiology. SUBSTANCE: one should carry out anesthesiological assistance in children with burns at the background of their kept own breathing, introductory narcosis is conducted due to intramuscular injection of ketamine at 3-5 mg/kg and sibazone at 0.2-0.5 mg/kg body weight, as for basis-narcosis it should be supplemented with intramuscular introduction of sodium oxybutyrate at the dosage of 30-60 mg/kg and ketamine at the dosage of 2-3 mg/kg along with sibazone at 0.2-0.3 mg/kg. The present innovation provides adequate anesthesia, stability of both intraoperational and postoperational hemodynamics. Moreover, patients wake up without any psychotic reactions after operation conducted. EFFECT: higher efficiency. 2 tbl
This cross-sectional study explores the impact of FTO gene single nucleotide polymorphisms (SNPs) rs9939609 and rs1421085 on dietary habits contributing to obesity risk in Thai adults. The study enrolled 384 participants from Bangkok, categorized as non-obese (BMI < 25 kg/m2) or obese (BMI ≥ 25 kg/m2) based on WHO Asia Pacific Guidelines. Genotyping for FTO variants was performed using DNA from blood samples. While both SNPs adhered to Hardy-Weinberg equilibrium, the association between risk alleles and anthropometric measurements was not statistically significant. However, risk allele carriers showed significantly higher intakes of sugar and saturated fat compared to homozygous dominant individuals. In the obese group, the odds ratio for high-sugar intake was 2.22 (95% CI 1.13-4.37, p = 0.021) for rs9939609 risk allele carriers. For high-saturated fat intake, the odds ratio was 1.86 (95% CI 1.02-3.40, p = 0.041). Similar associations were observed for rs1421085. Risk allele carriers also exhibited significantly higher leptin levels (p < 0.043) and a positive correlation with myeloperoxidase levels (p < 0.038). These findings highlight the complex relationship between FTO risk alleles, increased consumption of sugar and saturated fat, and obesity-related parameters. The insights emphasize the importance of considering both genetic and dietary factors in obesity prevention strategies.
An ink comprises graphene or graphene oxide particles dispersed in a carrier, wherein a viral active or antimicrobial component is adhered to the particles. Typically, the viral active or antimicrobial component comprises metal ions or nanoparticles (especially silver nanoparticles), curcumin, or hypericin and may comprise a capping agent, e.g. polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, or EDTA. The carrier may be a solvent and the nanoparticles may be 1-100 nm in size. The surface of the graphene or graphene oxide may be functionalised with thiol, hydroxyl, carboxyl, epoxy, or carbonyl groups. In another aspect, an article comprises a substrate having a coating that comprises a viral active or antimicrobial component on graphene or graphene oxide particles. The article may be a filter or a face mask. Use of a composition comprising a viral active component adhered to graphene or graphene oxide particles as an antiviral or viricide for Sars-CoV-2 is also claimed.
The patients in the virological monitoring arm will have routine laboratory monitoring as in the standard monitoring arm and in addition will have a viral load test performed every 6 months while in treatment. The first test will be done 6 months after initiating ART.
Pulmonary hamartomas are the most common benign tumors of the lung, typically solitary with a diameter≤4 cm, and rarely undergo malignant transformation. We reported a case of multiple pulmonary hamartomas with malignant transformation of a giant pulmonary hamartoma (approximately 10 cm×12 cm in size). The patient was a 61-year-old female who sought medical attention for the discovery of multiple lesions in the right lung during a routine examination. Computed tomography revealed multiple soft tissue density lesions in the right lung. Surgical resection was performed to remove the lower lobe of the right lung and the lesion located in the posterior segment of the right upper lobe. The pathological results indicated that the right lower lobe lesion had undergone malignant transformation to a high-grade chondrosarcoma originating from a hamartoma, while the right upper lobe lesion remained a hamartoma. By analyzing this case together with the relevant literature, we aimed to emphasize the need for clinical awareness of the malignant potential of pulmonary hamartomas.
Prior to interim analysis 1 (IA1), there were 2 treatment regimens: Regimen 1 (10 milligram \[mg\] once daily, 7 days on/7 days off); and Regimen 2 (6 mg once daily for 28 days). Following IA1, Regimen 1 is closed for further enrollment and starting dose of Regimen 2 is increased to 8 mg once daily for 28 days on a 28-day cycle (referred to as Regimen 3). Participants who enrolled in DDI substudy will receive pretreatment with single doses of midazolam (Day -2) and metformin (Day -1). Participants enrolled in DDI substudy will receive 8 mg erdafitinib treatment from Day 1 to Day 15, single doses of midazolam 2.5 mg (Day 13) and metformin 1000 mg (Day 14) and erdafitinib treatment will continued until disease progression. Participants who completed the DDI substudy and continue to benefit from erdafitinib treatment, will continue to receive erdafitinib in long-term extension (LTE) phase.
Postoperative pain management is very important in patients underwent orthognathic surgery. Effective pain control provides early mobilization, shorter hospital stay and it increases the satisfaction of the patients. Opioid agents may provide effective pain management, however opioid agents have undesirable adverse effects such as respiratory depression, sedation, constipation, nausea and vomiting etc. Ultrasound (US) -guided regional anesthesia techniques may be preferred for pain management in patients underwent orthognathic surgery. Regional anesthesia techniques may provide effective postoperative pain management as a part of multimodal analgesia regimens. US-guided bilateral superficial cervical plexus block (SCPB) have been performed for several head and neck surgeries and it provides effective pain control. The cervical plexus presents between the longus capitis and middle scalene muscles, under the prevertebral fascia. It is formed by the C2-4 cervical spinal nerves. There are the end points of these nerves in the interfascial area under the SCM. Thus, the superfascial branches of the cervical plexus may be blocked by injecting local anesthetic under the SCM. Cervical plexus may be blocked with deep or superficial technique. The deep CPB is defined as a paravertebral block. The deep branches may be targeted by this method. However it has some major disadvantages such as intravascular injection, epidural or subarachnoid injection, and phrenic nerve palsy, due to the deepness of the injection. Otherwise; SCPB is a superficial method and it has lower complication rate compared to the deep CPB. In an anatomical study, it has been reported that with SCPB there was spread of dye into the deep cervical fascia. The authors emphasized that this mechanism may explain the efficacy of the SCPB. Thus, with the SCPB both the superficial branches and the deep nerve roots may be blocked. Therefore, SCPB may provide effective pain management following orthognathic surgery. In the literature, there are no randomized clinical studies about pain management with US-guided SCPB after orthognathic surgery, yet.

The aim of this study is to evaluate the efficacy of the US-guided SCPB for postoperative analgesia management after orthognathic surgery. The primary aim is to evaluate postoperative opioid consumption and the secondary aim is to evaluate postoperative pain scores (VAS), adverse effects related with opioids (allergic reaction, nausea, vomiting) compared to no intervention control group.